Location History:
- Kaminokawa-machi, JP (2004 - 2009)
- Tochigi, JP (2001 - 2011)
Company Filing History:
3 out of 2,596 
3 out of 200 
2 out of 441 
Years Active: 2001-2011
Title: Masahiko Kinosaki: Innovator in Osteoclast Activity Inhibition
Introduction
Masahiko Kinosaki is a prominent inventor based in Tochigi, Japan. He has made significant contributions to the field of medical science, particularly in the area of bone health. With a total of 10 patents, Kinosaki's work focuses on innovative methods to treat diseases characterized by bone loss.
Latest Patents
Kinosaki's latest patents include methods of inhibiting osteoclast activity. These methods disclose techniques for inhibiting osteoclastogenesis and the activity of osteoclasts. His research also includes methods for treating patients with diseases characterized by bone loss. According to these methods, an effective amount of a TRANCE/RANK inhibitor is administered to the patient to inhibit osteoclastogenesis. Additionally, he has developed pharmaceutical compositions that comprise TRANCE/RANK inhibitors in amounts effective for this purpose. Furthermore, Kinosaki's patents detail methods for modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in individuals, which also involve administering TRANCE/RANK inhibitors.
Career Highlights
Throughout his career, Kinosaki has worked with esteemed institutions such as the University of Pennsylvania and Daiichi Pharmaceutical Co., Ltd. His innovative approaches have garnered attention in the scientific community, contributing to advancements in medical treatments for bone-related diseases.
Collaborations
Kinosaki has collaborated with notable colleagues, including Kyoji Yamaguchi and Masaaki Goto. These partnerships have further enriched his research and development efforts in the field.
Conclusion
Masahiko Kinosaki's contributions to the field of osteoclast activity inhibition highlight his role as a leading inventor in medical science. His innovative methods and collaborations continue to pave the way for advancements in treating bone loss diseases.